Half-year report · Q2

Period2024-03-01 → 2024-08-31
Filed2024-10-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥22.7bn2024-03-01 → 2024-08-31Cons.Net sales
Revenue¥39.9bn2023-03-01 → 2024-02-29Cons.Net sales (5-year summary)
Revenue¥17.5bn2023-03-01 → 2023-08-31Cons.Net sales
Operating income¥828m2024-03-01 → 2024-08-31Cons.Operating income
Operating income¥603m2023-03-01 → 2023-08-31Cons.Operating income
Ordinary income¥853m2024-03-01 → 2024-08-31Cons.Ordinary income
Ordinary income¥1.8bn2023-03-01 → 2024-02-29Cons.Ordinary income loss (5-year summary)
Ordinary income¥697m2023-03-01 → 2023-08-31Cons.Ordinary income
Profit before tax¥1.1bn2024-03-01 → 2024-08-31Cons.Income before income taxes
Profit before tax¥776m2023-03-01 → 2023-08-31Cons.Income before income taxes
Net income (owners)¥710m2024-03-01 → 2024-08-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥1.0bn2023-03-01 → 2024-02-29Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥444m2023-03-01 → 2023-08-31Cons.Profit loss attributable to owners of parent
Net income¥728m2024-03-01 → 2024-08-31Cons.Profit loss
Net income¥469m2023-03-01 → 2023-08-31Cons.Profit loss
Total assets¥33.1bnat 2024-08-31Cons.Assets
Total assets¥31.7bnat 2024-02-29Cons.Assets
Total assets¥28.5bnat 2023-08-31Cons.Total assets (5-year summary)
Total liabilities¥18.7bnat 2024-08-31Cons.Liabilities
Total liabilities¥17.8bnat 2024-02-29Cons.Liabilities
Net assets / equity¥14.4bnat 2024-08-31Cons.Net assets
Net assets / equity¥13.8bnat 2024-02-29Cons.Net assets
Net assets / equity¥13.1bnat 2023-08-31Cons.Net assets (5-year summary)
Cash and deposits¥8.2bnat 2024-08-31Cons.Cash and deposits
Cash and deposits¥7.7bnat 2024-02-29Cons.Cash and deposits
Cash & equivalents¥8.1bnat 2024-08-31Cons.Cash and cash equivalents
Cash & equivalents¥7.6bnat 2024-02-29Cons.Cash and cash equivalents
Cash & equivalents¥6.5bnat 2023-08-31Cons.Cash and cash equivalents
Cash & equivalents¥6.3bnat 2023-02-28dCons.Cash and cash equivalents
Operating cash flow¥1.5bn2024-03-01 → 2024-08-31Cons.Net cash provided by used in operating activities
Operating cash flow¥4.3bn2023-03-01 → 2024-02-29Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥848m2023-03-01 → 2023-08-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥675m2024-03-01 → 2024-08-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥3.2bn2023-03-01 → 2024-02-29Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥338m2023-03-01 → 2023-08-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥354m2024-03-01 → 2024-08-31Cons.Net cash provided by used in financing activities
Financing cash flow¥278m2023-03-01 → 2024-02-29Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥217m2023-03-01 → 2023-08-31Cons.Net cash provided by used in financing activities
EPS (basic)¥188.752024-03-01 → 2024-08-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥276.72023-03-01 → 2024-02-29Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥118.262023-03-01 → 2023-08-31Cons.Basic earnings loss per share (5-year summary)
Equity ratio41.6%at 2024-08-31Cons.Equity to asset ratio (5-year summary)
Equity ratio41.8%at 2024-02-29Cons.Equity to asset ratio (5-year summary)
Equity ratio43.9%at 2023-08-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-03-01 → 2024-08-31−¥401m
Reconciling Itemsreconcilingrevenue intersegment2024-03-01 → 2024-08-31−¥401m
Reconciling Itemsreconcilingsegment profit2024-03-01 → 2024-08-31−¥110m
jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segmentrevenue2024-03-01 → 2024-08-31¥11.9bn
jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segmentrevenue external2024-03-01 → 2024-08-31¥11.9bn
jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segmentsegment profit2024-03-01 → 2024-08-31¥551m
jpcrp040300-q2r_E03443-000Health Carereportable segmentrevenue2024-03-01 → 2024-08-31¥4.0bn
jpcrp040300-q2r_E03443-000Health Carereportable segmentrevenue external2024-03-01 → 2024-08-31¥4.0bn
jpcrp040300-q2r_E03443-000Health Carereportable segmentrevenue intersegment2024-03-01 → 2024-08-31¥300,000
jpcrp040300-q2r_E03443-000Health Carereportable segmentsegment profit2024-03-01 → 2024-08-31¥128m
jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segmentrevenue2024-03-01 → 2024-08-31¥7.1bn
jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segmentrevenue external2024-03-01 → 2024-08-31¥6.7bn
jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segmentrevenue intersegment2024-03-01 → 2024-08-31¥399m
jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segmentsegment profit2024-03-01 → 2024-08-31¥194m
jpcrp040300-q2r_E03443-000Real Estatereportable segmentrevenue2024-03-01 → 2024-08-31¥93m
jpcrp040300-q2r_E03443-000Real Estatereportable segmentrevenue external2024-03-01 → 2024-08-31¥91m
jpcrp040300-q2r_E03443-000Real Estatereportable segmentrevenue intersegment2024-03-01 → 2024-08-31¥2m
jpcrp040300-q2r_E03443-000Real Estatereportable segmentsegment profit2024-03-01 → 2024-08-31¥65m
Total Of Reportable Segments And Otherssegment totalrevenue2024-03-01 → 2024-08-31¥23.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-03-01 → 2024-08-31¥22.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-03-01 → 2024-08-31¥401m
Total Of Reportable Segments And Otherssegment totalsegment profit2024-03-01 → 2024-08-31¥938m
Reconciling Itemsreconcilingrevenue2023-03-01 → 2023-08-31−¥472m
Reconciling Itemsreconcilingrevenue intersegment2023-03-01 → 2023-08-31−¥472m
Reconciling Itemsreconcilingsegment profit2023-03-01 → 2023-08-31−¥296m
jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segmentrevenue2023-03-01 → 2023-08-31¥11.9bn
jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segmentrevenue external2023-03-01 → 2023-08-31¥11.9bn
jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segmentsegment profit2023-03-01 → 2023-08-31¥688m
jpcrp040300-q2r_E03443-000Health Carereportable segmentrevenue2023-03-01 → 2023-08-31¥3.9bn
jpcrp040300-q2r_E03443-000Health Carereportable segmentrevenue external2023-03-01 → 2023-08-31¥3.9bn
jpcrp040300-q2r_E03443-000Health Carereportable segmentrevenue intersegment2023-03-01 → 2023-08-31¥300,000
jpcrp040300-q2r_E03443-000Health Carereportable segmentsegment profit2023-03-01 → 2023-08-31¥111m
jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segmentrevenue2023-03-01 → 2023-08-31¥2.1bn
jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segmentrevenue external2023-03-01 → 2023-08-31¥1.6bn
jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segmentrevenue intersegment2023-03-01 → 2023-08-31¥470m
jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segmentsegment profit2023-03-01 → 2023-08-31¥34m
jpcrp040300-q2r_E03443-000Real Estatereportable segmentrevenue2023-03-01 → 2023-08-31¥93m
jpcrp040300-q2r_E03443-000Real Estatereportable segmentrevenue external2023-03-01 → 2023-08-31¥91m
jpcrp040300-q2r_E03443-000Real Estatereportable segmentrevenue intersegment2023-03-01 → 2023-08-31¥2m
jpcrp040300-q2r_E03443-000Real Estatereportable segmentsegment profit2023-03-01 → 2023-08-31¥66m
Total Of Reportable Segments And Otherssegment totalrevenue2023-03-01 → 2023-08-31¥17.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-03-01 → 2023-08-31¥17.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-03-01 → 2023-08-31¥472m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-03-01 → 2023-08-31¥899m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 515
ItemContextValueUnit
Purchase of property plant and equipment inv cfPrior1YTDDuration-154156000JPY
Purchase of property plant and equipment inv cfCurrentYTDDuration-465027000JPY
Proceeds from sales of property plant and equipment inv cfPrior1YTDDuration-JPY
Proceeds from sales of property plant and equipment inv cfCurrentYTDDuration2255000JPY
Purchase of intangible assets inv cfPrior1YTDDuration-5013000JPY
Purchase of intangible assets inv cfCurrentYTDDuration-22651000JPY
Purchase of investment securities inv cfPrior1YTDDuration-405326000JPY
Purchase of investment securities inv cfCurrentYTDDuration-455290000JPY
Proceeds from sales of investment securities inv cfPrior1YTDDuration422748000JPY
Proceeds from sales of investment securities inv cfCurrentYTDDuration470380000JPY
Proceeds from purchase of investments in subsidiaries resulting in change in scope of consolidation inv cfPrior1YTDDuration-JPY
Proceeds from purchase of investments in subsidiaries resulting in change in scope of consolidation inv cfCurrentYTDDuration153474000JPY
Payments of loans receivable inv cfPrior1YTDDuration-JPY
Payments of loans receivable inv cfCurrentYTDDuration-500000000JPY
Payments for lease and guarantee deposits inv cfPrior1YTDDuration-3084000JPY
Payments for lease and guarantee deposits inv cfCurrentYTDDuration-16951000JPY
Proceeds from collection of lease and guarantee deposits inv cfPrior1YTDDuration11193000JPY
Proceeds from collection of lease and guarantee deposits inv cfCurrentYTDDuration34399000JPY
Other net inv cfPrior1YTDDuration-204516000JPY
Other net inv cfCurrentYTDDuration124007000JPY
Net cash provided by used in investment activitiesPrior1YTDDuration-338155000JPY
Net cash provided by used in investment activitiesCurrentYTDDuration-675404000JPY
Net increase decrease in short term loans payable fin cfPrior1YTDDuration20000000JPY
Net increase decrease in short term loans payable fin cfCurrentYTDDuration-215000000JPY
Proceeds from long term loans payable fin cfPrior1YTDDuration1350000000JPY
Proceeds from long term loans payable fin cfCurrentYTDDuration1200000000JPY
Repayment of long term loans payable fin cfPrior1YTDDuration-1495993000JPY
Repayment of long term loans payable fin cfCurrentYTDDuration-1231970000JPY
Repayments of lease obligations fin cfPrior1YTDDuration-16252000JPY
Repayments of lease obligations fin cfCurrentYTDDuration-13561000JPY
Cash dividends paid fin cfPrior1YTDDuration-75140000JPY
Cash dividends paid fin cfCurrentYTDDuration-93953000JPY
Net cash provided by used in financing activitiesPrior1YTDDuration-217387000JPY
Net cash provided by used in financing activitiesCurrentYTDDuration-354484000JPY
Net increase decrease in cash and cash equivalentsPrior1YTDDuration292008000JPY
Net increase decrease in cash and cash equivalentsCurrentYTDDuration471677000JPY
Cash and cash equivalentsPrior2YearInstant6253102000JPY
Cash and cash equivalentsPrior1YearInstant7589368000JPY
Increase decrease in cash and cash equivalents resulting from change of scope of consolidation ccePrior1YTDDuration-JPY
Increase decrease in cash and cash equivalents resulting from change of scope of consolidation cceCurrentYTDDuration14380000JPY
Cash and cash equivalentsPrior1QuarterInstant6545111000JPY
Cash and cash equivalentsCurrentQuarterInstant8075427000JPY
Directors compensations sgaPrior1YTDDuration127283000JPY
Directors compensations sgaCurrentYTDDuration155840000JPY
Payroll and allowances sgaPrior1YTDDuration285172000JPY
Payroll and allowances sgaCurrentYTDDuration710672000JPY
Provision for bonuses sgaPrior1YTDDuration18706000JPY
Provision for bonuses sgaCurrentYTDDuration66525000JPY
Retirement benefit expenses sgaPrior1YTDDuration5407000JPY
Retirement benefit expenses sgaCurrentYTDDuration21391000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-02-29pass
balance sheet identityconsolidated 2024-08-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-02-29pass
statement vs summary · net assetsconsolidated 2024-08-31pass
statement vs summary · net income attributable to parentconsolidated 2023-03-01/2023-08-31pass
statement vs summary · net income attributable to parentconsolidated 2024-03-01/2024-08-31pass
statement vs summary · operating cash flowconsolidated 2023-03-01/2023-08-31pass
statement vs summary · operating cash flowconsolidated 2024-03-01/2024-08-31pass
statement vs summary · revenueconsolidated 2023-03-01/2023-08-31pass
statement vs summary · revenueconsolidated 2024-03-01/2024-08-31pass
statement vs summary · total assetsconsolidated 2024-02-29pass
statement vs summary · total assetsconsolidated 2024-08-31pass